DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study

Dexcom's CONNECT trial results, published in The New England Journal of Medicine, demonstrate that its G7 continuous glucose monitoring system achieves a 1.6% A1C reduction in non-insulin-treated Type 2 diabetes patients, with 97% adherence at 26 weeks. The findings support broader CGM adoption and could expand market opportunities, though success depends on physician adoption and insurance coverage. The global CGM market is projected to grow from $13.4 billion in 2025 to $41.4 billion by 2033.